# US 2005/0037495 A1 · Human CNS cell lines and methods of use therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0037495 A1
- Document ID: US20050037495A1
- Status: Published application
- Kind: A1
- Application number: 10/813,203
- Filed: 2004-03-29
- Published: 2005-02-17
- Earliest claimed: 1996-09-03
- Assignees: Signal Pharmaceuticals, LLC
- Inventors: Dinah Sah; Fred Gage; Jasodhara Ray
- Web page: https://patentgrep.com/patent/US20050037495A1

## CPC

- C12N 5/0623: {Stem cells}
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/13: Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C12N 2501/135: Platelet-derived growth factor [PDGF]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Conditionally-immortalized human CNS progenitor cell lines are provided. Such cell lines, which may be clonal, may be used to generate neurons and/or astrocytes. Such cell lines and/or differentiated cells may be used for the development of therapeutic agents to prevent and treat a variety of CNS-related diseases. Such cell lines and/or differentiated cells may also be used in assays and for the general study of CNS cell development, death and abnormalities.

## Claims

### Claim at position 1

1-11. (Canceled)

### Claim 12

A method for introducing a CNS cell into a mammal, comprising administering to a mammal a cell produced by a method comprising:
(a) plating human CNS progenitor cells on a surface that permits proliferation, said surface being tissue culture plastic or a surface treated with fibronectin;
(b) adding serum-free growth medium to the cells;
(c) allowing the CNS progenitor cells to proliferate in the serum-free medium;
(d) transfecting the cells with DNA encoding a selectable marker and regulatable growth-promoting gene, wherein the growth-promoting gene is selected from the group consisting of SV40 large T antigen, v-myc, N-myc, c-myc, p53, polyoma large T antigen, E1a adenovirus and E7 protein of human papilloma virus;
(e) passaging the transfected cells onto a substrate; and
(f) adding serum-free growth medium containing one or more proliferation-enhancing factors to the transfected cells, wherein said proliferation-enhancing factors are selected from the group consisting of FGF-2, PDGF, EGF, medium conditioned by perpetualized adult rat hippocampal progenitor cells, and a combination thereof, therefrom producing a conditionally-immortalized human CNS progenitor cell.

### Claim 13

A method for introducing a CNS cell into a mammal, comprising administering to a mammal a conditionally-immortalized clonal human CNS progenitor cell capable of differentiation into neurons and astrocytes.

### Claim 14

A method for treating a patient, comprising administering to a patient a cell produced by a method comprising:
(a) plating human CNS progenitor cells on a surface that permits proliferation, said surface being tissue culture plastic or a surface treated with fibronectin;
(b) adding serum-free growth medium to the cells;
(c) allowing the CNS progenitor cells to proliferate in the serum-free medium;
(d) transfecting the cells with DNA encoding a selectable marker and regulatable growth-promoting gene, wherein the growth-promoting gene is selected from the group consisting of SV40 large T antigen, v-myc, N-myc, c-myc, p53, polyoma large T antigen, E1a adenovirus and E7 protein of human papilloma virus;
(e) passaging the transfected cells onto a substrate; and
(f) adding serum-free growth medium containing one or more proliferation-enhancing factors to the transfected cells, wherein said proliferation-enhancing factors are selected from the group consisting of FGF-2, PDGF, EGF, medium conditioned by perpetualized adult rat hippocampal progenitor cells, and a combination thereof, therefrom producing a conditionally-immortalized human CNS progenitor cell.

### Claim 15

A method for treating a patient, comprising administering to a mammal a conditionally-immortalized clonal human CNS progenitor cell capable of differentiation into neurons and astrocytes.

### Claim 16 (depends on 15)

A method according to claim 15 wherein the patient is afflicted with a pathological condition where neurons have degenerated.

### Claim 17 (depends on 16)

A method according to claim 16 wherein the pathological condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amylotrophic lateral sclerosis, stroke and traumatic head injury.

### Claim at position 8

18-32. (Canceled)
